XYMOGEN EP Exclusive Patented Dietary Supplement Artriphen Clinically Tested to Support Healthy Joint Function, 90 and 180 capsule bottles

FDA recall notice · announced June 19, 2013 · Atlantic Pro Nutrients, Inc. Dba Xymogen

Class I FDA/FSIS Class I: reasonable probability that use will cause serious adverse health consequences or death.

The product

XYMOGEN EP Exclusive Patented Dietary Supplement Artriphen Clinically Tested to Support Healthy Joint Function, 90 and 180 capsule bottles

Reason for recall

Undeclared Soy and Milk on the label.

Notes

Distribution: AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, IA, IL IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, NC, NJ, NM, NY, OH, OK, PA, RI, SC, TN, TX, UT, VA, WA, WI, WV, WY, District of Columbia and Hawaii
Lot/code information: All SKUs
Quantity: 16,268 units
Status: Terminated
Products in this recall event:
- XYMOGEN EP Exclusive Patented Dietary Supplement Artriphen Clinically Tested to Support Healthy Joint Function, 90 and 180 capsule bottles (F-1523-2013)

Source: U.S. Food and Drug Administration public recall data. This page reports official records and is not legal, medical, or repair advice.